The effects of berberine on p38MAPK pathway and COX-2 mRNA expression

姜昕,王启章,郭毅,李方明,王玲,马可夫,黄术良,张艳波
DOI: https://doi.org/10.3969/j.issn.1671-4008.2008.06.054
2008-01-01
Abstract:Objective To investigate the effect of berberine (BBR) on lipopolysaccharide induced p38MAPK and COX-2 mRNA and its protein expression in human peripheral blood monocytes (HPMC). Methods HPMC were isolated and cultured from whole blood and divided into 5 groups treated with null, LPS, LPS+BBR 25μmol/L, LPS+BBR 50μmol/L, LPS+BBR 100μmol/L respectively for 30minutes, 6 hours, 12 hours and 24 hours. Then monocytes were extracted for RT-PCR and Western blot analysis to examine COX-2 mRNA and protein activated expression of p38MAPK signaling pathway. Meanwhile, SB203580 (p38MAPK inhibitor) was incubated together with LPS stimulation to examine COX-2 mRNA and protein expression. Results At the four time points after treatment, the COX-2 mRNA and protein expression decreased at a low ebb at 12 hours after BBR treatment(P<0.05). On the other hand, with the increasing concentration of BBR treatment, the COX-2 expression decreased progressively(P<0.01). With BBR treatment at various time points (at 6h, 12h, 24h after treatment) and three levels of dosage, no difference was shown between BBR group and LPS group for p38MAPK protein expression(P>0.05). Human monocytes COX-2 mRNA and protein expression was inhibited statistically significantly while incubated with SB203580 (p38MAPK inhibitor) (P<0.05). Conclusion BBR inhibits COX-2 mRNA and its protein expression in a dose-dependent manner. COX-2 expression can be inhibited by p38MAPK signaling pathway inhibitor. P38MAPK may have no prominent relationship with the effect of BBR in HPMC.
What problem does this paper attempt to address?